Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II, Double Blind, Randomised, Placebo and Active Comparator Controlled Study to Assess the Safety and Efficacy of Three Doses of Dysport RU (20 U, 50 U, and 75 U) Administered as a Single Treatment Cycle to Improve the Appearance of Moderate to Severe Glabellar Lines

NCT01333397 is registered in ClinicalTrials.gov with Ipsen as lead sponsor.

NCT NCT01333397
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01333397 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II, Double Blind, Randomised, Placebo and Active Comparator Controlled Study to Assess the Safety and Efficacy of Three Doses of Dysport RU (20 U, 50 U, and 75 U) Administered as a Single Treatment Cycle to Improve the Appearance of Moderate to Severe Glabellar Lines
Lead sponsor
Ipsen
Phase
Phase 2
Overall status
Completed
Start date
March 31, 2011
Completion date
September 30, 2011
Enrollment
176 (actual)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

glabellar frown lines